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Lupus nephritis (LN) in systemic lupus erythematosus (SLE)
remains a major cause of morbidity and end-stage renal
disease. While therapies such as corticosteroids,
cyclophosphamide, and mycophenolate mofetil have
improved outcomes, a significant proportion of patients have
refractory disease or are unable to tolerate these agents.
Limitations in existing therapies, along with advances in our
understanding of the immunopathogenesis of SLE, have
resulted in the development of new immunosuppressive and
immunomodulatory treatments for SLE/LN. Dysfunction of
the B lymphocyte—an important component of adaptive
immunity—is thought to be important in the pathogenesis of
SLE/LN. The goal of this study is to review our current
understanding of the role of B cells in the pathogenesis of
SLE, and to discuss new and emerging therapies that
selectively target B cells in patients with SLE/LN. Novel
strategies discussed include B-cell depletion by the
monoclonal antibodies to B-cell markers, rituximab and
epratuzumab; ‘pharmapheresis’ of pathogenic antibodies to
dsDNA, by abetimus; blockade of T-cell costimulation of B
cells by abatacept, belatacept, BG9588, and IDEC-131; and
blockade of B-cell stimulation by belimumab. Preliminary
results are promising, but in the absence of large controlled
trials, caution must be exercised prior to the widespread use
and acceptance of these treatments.
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Renal involvement in systemic lupus erythematosus (SLE)
remains a major cause of end-stage renal disease and is
associated with a greater than four-fold increase in mortality
in recent series.1 While clinical outcomes for proliferative
lupus nephritis (LN) have improved since the 1990s with
widespread adoption of the National Institutes of Health
treatment strategy using intravenous cyclophosphamide and
corticosteroids,2–4 up to 25% of patients fail to respond to
this treatment.2,3,5 Furthermore, these therapies are limited
by the high incidence of serious side effects including
premature gonadal failure5,6 and malignancy.7 In recent
years, many new immunosuppressive therapies have been
evaluated for LN and many more are under consideration.
Mycophenolate mofetil, a selective, reversible, noncompeti-
tive inhibitor of purine synthesis that restricts lymphocyte
and leukocyte proliferation, has been accepted as an
alternative therapy to cyclophosphamide. While mycophe-
nolate offers a superior side effect profile, with fewer serious
infections and hospitalizations, the majority of patients did
not achieve full remission in the largest controlled trial to
date.8 Limitations in existing therapies, as well as rapid
advances in our understanding of the immunopathogenesis
of SLE over the past two decades, have stimulated intense
interest in developing new immunosuppressive and immu-
nomodulatory treatments for SLE and LN. B lymphocytes are
intimately involved in the pathogenesis of SLE/LN.9–13 We
aim to review our current understanding of the role of B cells
in the pathogenesis of SLE, and to discuss new and emerging
therapies that selectively target B cells in patients with SLE/
LN (summarized in Figure 1 and Table 1).
ROLE OF B CELLS IN PATHOGENESIS OF SLE
B lymphocytes are components of the adaptive immune
system. They arise from hematopoietic stem cells throughout
life and express a diverse repertoire of immunoglobulins
against a wide array of pathogens, and function as antigen
presenting cells (APCs) to T lymphocytes. During develop-
ment, the antigenic specificity of a B cell is determined
through the process of gene rearrangement, resulting in
antigen-specific cell-surface receptors. Some of these recep-
tors may display specificity for ‘self ’-antigens. B-cell tolerance
occurs through the processes of ‘passive tolerance,’ when the
replication of autoreactive immature B cells in the bone
marrow or in the peripheral lymphoid tissue is controlled
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due to anergy or apoptosis, and ‘active tolerance’ mediated by
CD4þ regulatory T cells, which suppress activation of the
immune system and prevent pathological self-reactivity.14,15
B-cell activation, on the other hand, is triggered by antigen,
requires a second signal from a cognate CD4þ T cell that has
the same specificity, and is facilitated by secretion of
cytokines such as interferon-g and interleukin-4.16 These
events drive the naı¨ve B cell to progress through the cell cycle,
promoting clonal expansion of the B cell. When stimulated
by an antigen some B cells are converted into the
immunoglobulin-secreting plasma cells that characterize the
humoral immune response. Other activated B cells migrate
into B-cell follicles where they coalesce into germinal centers,
undergo intense proliferation (the germinal center reaction),
and differentiate into either plasma cells or memory B cells in
the presence of appropriate costimulation by CD40 or B7.13
Through these processes, immune complexes are formed and
antigen is removed via recognition of immune complexes by
cells bearing the Fc-receptor (FcR), and activation of the
complement pathway occurs with concomitant recruitment
of effector leukocytes, resulting in inflammation. On the
other hand, when acting as APCs, B lymphocytes present
internalized and processed antigen to T cells via major
histocompatibility complex Class II in the setting of
appropriate costimulation, leading to a cascade of events
that result in activation of cognate T cells, release of
stimulatory cytokines, and recruitment of more B cells.13,17
Autoimmune disease occurs when the adaptive immune
response is mounted against ‘self ’-antigens, which cannot be
removed by effector mechanisms. The immune response is
sustained and chronic inflammation results. Effector re-
sponses in autoimmune tissue injury are mediated by T cells
or antibodies, which cause complement activation via
engagement of complement and FcR. Early models of
autoimmunity postulated the autoantibody as the key
component of disease pathogenesis. Evidence to support
this view included maternal transfer of autoantibodies
in neonatal lupus syndromes and animal models of
passive transfer of disease through autoantibody inoculation.
Indirect evidence was offered in the observation that SLE
disease activity correlates with titers of anti-dsDNA and that
immune complexes are found in tissues affected by disease,
such as the glomeruli. However, evidence for an antibody-
independent role for B cells is suggested by animal models,
that is, an MRL lpr/lpr lupus prone mouse with nonsecretory
plasma cells developed evidence of autoimmune disease,18 yet
B-cell-deficient MRL lpr/lpr mice did not.19 B cells producing
autoantibodies in SLE have undergone extensive clonal
expansion, suggesting that the antibodies are produced in
response to chronic stimulation of B cells by antigen and
costimulatory autoreactive CD4þ T cells—therefore sug-
gesting an important role for the autoreactive T cell in
addition to B lymphocytes. Another B-cell-related functions
likely to be important in the pathogenesis of SLE is cytokine
release, particularly proinflammatory interleukin-10, tumor
necrosis factor (TNF)-a, and interleukin-6, all of which are
produced in high levels in SLE, and BlyS/BAFF (B-
lymphocyte stimulator/B-cell activating factor; a TNF-family
cytokine that promotes B-cell maturation and survival and
plasma cell differentiation).20 The role of the B lymphocyte as
an APC is also likely to be essential in the development of
autoimmunity. In experimental models of autoimmune
arthritis, the APC function of B cells was essential for the
development of disease, while the antibody-secreting func-
tion was not.18,21 Ultimately, activated B cells can aggregate
into ectopic lymph node-like structures containing plasma-
blasts, memory B cells, and plasma cells are observed in sites
with chronic inflammation. This local generation of B cells
can exacerbate disease through localized autoantibody
generation, and stimulation of proinflammatory cytokines
and effector leukocytes.
CLINICAL STUDIES OF B-CELL THERAPIES IN SLE/LN
B-cell depletion with anti-CD20 monoclonal antibody
(rituximab)
Given substantial evidence for the role of B cells in the
pathogenesis of SLE and the recent development of mono-







Figure 1 | B-lymphocyte-specific therapeutic targets in SLE.
B-lymphocyte depletion (1) rituximab, (2) epratuzumab; reduction of
dsDNA titers, (3) LJP 394/abetimus; blockade of T-cell costimulation
(4) CTLA4-Ig (abatacept and belatacept), (5) IDEC131 and BG9588;
blockade of B-cell stimulation, (6) belimumab.
Table 1 | New and evolving therapies for lupus nephritis




Pharmapheresis of antibodies to dsDNA
Abetimus
Blockade of T-cell costimulation
Abatacept, Belatacept
BG9588, IDEC-131
Blockade of B-cell stimulation
Belimumab
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depletion is an intuitive and attractive approach to SLE
treatment. These drugs were initially developed for treatment
of B-cell malignancies; however, there is now considerable
clinical experience with these agents in autoimmune disease.
Rituximab is a chimeric antibody directed against the CD20
antigen on the surface of pre-B cells and mature B
lymphocytes. CD20 is a tetraspan cell surface molecule of
33–37 kDa molecular weight which may function as a calcium
channel.22 Stem cells, pro-B cells, and plasma cells do not
bear CD20 molecules and are unaffected by the immediate
effects of therapy. Rituximab leads to profound depletion of
B-cell subsets both in vitro and in vivo.23 In vitro B-cell
depletion by rituximab occurs through antibody-dependent
cell cytotoxicity, complement-dependent cytotoxicity, or
apoptosis.13 In humans, the degree of B-cell depletion by
rituximab varies with polymorphisms of the FcR(gam-
ma)IIIA allele, suggesting that antibody-dependent cell
cytotoxicity is an important mechanism of B-cell depletion
in vivo.24,25 Of interest, CD20 null mice have no obvious
phenotype, and have normal B-cell responses;26 thus the
function of CD20 remains unclear.
Rituximab was first used successfully in the treatment of
B-cell malignancies.23,27,28 The most commonly used dosing
regimen, 375 mg m2 intravenous infusion given weekly for a
total of 4 weeks, is based on dosing in clinical trials in non-
Hodgkin’s lymphoma;29 however, an alternative regimen—
1000 mg given twice in a 2-week interval—has been used
with success in rheumatoid arthritis.30 T1/2 is about 20 days,
with drug levels measurable for as long as 6 months after
treatment and B-cell depletion, sometimes lasting longer than
1 year.23,31 In oncologic protocols, patients have been re-
dosed with rituximab on the basis of clinical recurrence;
experience in dosing and dose intervals in autoimmune
diseases is limited. Clinically, administration of rituximab is
generally followed by depletion of B lymphocytes to levels less
than 5 ml1—an effect generally seen within days. Other
blood elements are unaffected, including neutrophils and T
lymphocytes. There is no significant early effect on serum
immunoglobulin levels,23 which may account for the relative
protection from infectious complications and suggests that
the mechanism of therapeutic effect of rituximab in
autoimmune disease is independent of decreases in autoanti-
body production.32
Evidence for the efficacy of rituximab in SLE has been
mixed. The initial report of successful management of SLE
with rituximab was in an 18-year-old female patient with
SLE-associated autoimmune hemolytic anemia resistant to
corticosteroids, cyclosporine A, and intravenous immuno-
globulin. After treatment with two doses of rituximab
(375 mg m2), she remained disease-free for 7 months.33 To
date, more than 100 patients have been treated with
rituximab, either alone or in combination with steroids and
cyclosphosphamide, in multiple subsequent small open-label
trials. Patient populations have been heterogeneous. All trials
have investigated the use of rituximab as an induction agent,
rather than for maintenance therapy. Some patients have
shown improvement in disease activity in response to
rituximab, with improved disease activity scores, urinary
protein excretion, and anti-dsDNA titers. Occurrence of
adverse events has been minimal. Many other patients,
however, have failed to respond or have responded only
partially (Table 2).24,34–42 There can be significant variability
in the degree of B-cell depletion; factors affecting degree of
response to rituximab include tumor burden (in lymphoma
patients), amount of available circulating CD20, human anti-
chimeric antibodies (HACA), proteinuria, and genetic
polymorphisms of FcR(gamma)IIIA leading to a phenotype
with low affinity to rituximab.24,34,43 Mechanisms other than
B-cell depletion may be important in the therapeutic effect of
rituximab, including downregulation of costimulatory T cells
and shifts in B-cell population subsets.39,40 A multicenter
randomized placebo-controlled trial of rituximab in addition
to MMF in proliferative LN is currently underway (ClinicalTrials.
gov Identifier: NCT00282347).
Use of rituximab in autoimmune disease is associated with
an increase in the incidence of HACA. The development of
HACA, rare in the early lymphoma trials, has occurred
frequently in autoimmune diseases. In the University of
Rochester trial more than one-third of SLE patients
developed high titers of HACA, ranging from 600 to
9900 ng ml1 in 6/18 patients, while five others had titers
that were low but detectable. It is not yet clear whether
development of HACA limits the efficacy of B-cell depletion34
or whether HACA are associated with adverse events. No
major infectious complications have been reported to date in
adult patients with SLE treated with rituximab. However, a
recent Food and Drug Administration advisory warns of two
cases of progressive multifocal leukoencephalopathy in
patients with SLE nephritis treated with rituximab. Of note,
no patients with rheumatoid arthritis who received treatment
with rituximab developed progressive multifocal leukoence-
phalopathy (though it has been reported in lymphoma).44
Furthermore, there has been a high incidence of adverse
events related to rituximab therapy in a pediatric SLE
population, including three patients with infection requiring
hospitalization.45 Infusion reactions are common, particu-
larly during the first treatment, and can be minimized with
use of acetaminophen, anti-histamines, and corticosteroids
before infusion.
B-cell depletion with anti-CD 22 monoclonal antibody
(epratuzumab)
CD22, another B-cell surface restricted marker, is a 135 kDa
glycoprotein member of a class of adhesion molecules that
regulate B-cell activation and interact with T cells.46 CD22
has seven extracellular domains, and is rapidly internalized
when bound to its natural ligand (a co-stimulatory signal for
B cells). This marker is expressed in the cytoplasm of pro-B
and pre-B cells, and on the surface of mature B cells. Like
CD20, CD22 is not expressed on plasma cells. Unlike
CD20, the CD22 molecule can deliver intracellular signals,
either constitutively or after interaction with its ligand.
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Furthermore, CD22 modifies signaling through CD19/21 and
CD45.47 CD22-deficient mice show an increase in calcium
signaling in response to B-cell receptor ligation and have
reduced numbers of mature B cells peripherally and in the
bone marrow (suggesting a role in B-cell development).
Furthermore, B-cell life span is reduced, apoptosis enhanced,
and there is a predisposition to autoimmune disease.48 Thus
CD22 is an attractive target for therapy in autoimmune
disease not only because its expression is restricted to the
surface of mature B cells, but also for its potential function in
the pathogenesis of autoimmunity.47–49
Epratuzumab is a recombinant humanized monoclonal
immunoglobulin G (IgG) antibody to the CD22 antigen on B
cells. It has been shown to mediate antibody-dependent
cellular cytotoxicity in vitro and, but unlike rituximab,
mediates only partial B-cell depletion—a 35–40% reduction
in circulating B lymphocytes is seen in patients with SLE.50 It
is thought that epratuzumab modifies the function of B
lymphocytes without killing them, but the precise mechan-
isms of action remain unclear.49 Phase I/II clinical trials of
epratuzumab in patients with non-Hodgkin lymphoma have
demonstrated safety, with adverse events largely limited to
infusion-related reactions, and objective response in terms of
decreased tumor burden, and reduction of circulating B
cells.51 Epratuzumab has also been used with success in
combination with rituximab in refractory lymphoma.52 An
initial open-label nonrandomized single-center study of 14
Caucasian SLE patients has demonstrated safety and efficacy.
There were no patients with severe renal disease; four patients
had mild/stable proteinuria. On average, there was a
sustained 35% decrease in B-cell levels over 32 weeks of
follow-up. Development of anti-humanized antibodies was
not observed.50 A multicenter randomized placebo-con-
trolled clinical trial in SLE is underway (ClinicalTrials.gov
Identifier: NCT00383513).
Pharmapheresis of anti dsDNA antibodies with abetimus
A novel strategy in the treatment of SLE is inhibition of the
survival and activation of autoreactive B cells—the so-called
induction of tolerance. As reviewed above, two distinct
signals are necessary for the activation of T cells. The first
signal is binding of antigen to the B-cell receptor; the second
involves the interaction of receptor–ligand pairs on APCs
(including B cells) and cognate T cells. In the absence of this
second co-stimulatory signal, the B cell with affinity to the
specific antigen undergoes apoptopsis or becomes anergic.
A targeted strategy is to create a state of inactivation—anergy
or apoptosis—in B cells with receptors that express affinity to
dsDNA, thereby reducing titers of anti-dsDNA.
Abetimus (LJP 394, riquent) consists of four dsDNA
epitopes conjugated to a nonimmunogenic polyethylene
glycol platform. It acts by cross-linking anti-dsDNA surface
Table 2 | Trials of rituximab in patients with SLE and LN
Trial
n (Classes III, IV,V);
previous treatment Treatment regimen Main outcomes
Sfikakis et al.,
Greece34
10 (4, 6, 0)
All refractory to CS,
5/10 refractory to CY
4 weekly infusions of
375 mg m2+oral prednisolone
(0.5 mg kg1 day1 for 10 weeks
4 CR, 4 PR at 12 months follow-
up
Leandro et al., at
University College in
London30,31
24 (0, 16, 1)
All refractory to CS
and CY
500 mg 2 doses followed by
750 mg 2 doses; OR
1000 mg 2 doses total in
combination with CY (two
doses of 750 mg each) and
high-dose steroids
Significant reductions in BILAG
scores and anti-dsDNA titers;
nonsignificant decreases in
proteinuria at 6 months follow-
up.
One patient developed HACA





No previous CY. Most
received CS (varying
doses)
Dose escalation study (100, 375,
and 375 mg m2 4 doses) with
rituximab added to ongoing
therapies
Those who depleted B cells (11/
17) had decreases in SLAM and
dsDNA titers
6/18 developed high titer HACA
Vigna-Perez et al.,
Mexico32





500–1000 mg rituximab given
on days 1 and 15







Most refractory to CY
4 weekly infusions 375 mg m2
with one dose of CY (500 mg)
Proteinuria declined from mean
4.6 g/24 h to 0.45 g/24 h at 12
month follow-up
3 patients developed HACA
Willems et al.,
France40
11 (0, 6, 2); 7/8
previously treated
with CY
2–12 doses 350–450 mg m2 Mean age 13.9 years
6/8 had CR




CR, complete remission; CS, corticosteroids; CY, cyclophosphamide; HACA, human anti-chimeric antibodies; PR, partial remission; SLAM, systemic lupus activity measure.
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immunoglobulin receptor on B cells and triggering signal
tranduction pathways that lead to B-cell anergy or apoptosis
and reduced titers of anti-dsDNA titers in animal models of
SLE.53,54 The safety and efficacy of abetimus has been
evaluated in 13 controlled and uncontrolled trials, enrolling a
total of over 800 patients (reviewed in Cardiel55) with no
notable adverse events. A placebo-controlled trial of this
agent has shown significant reductions in anti-dsDNA
titers.56,57 In a 76 week double-blind, placebo-controlled
trial of abetimus in 230 patients with LN (including patients
with Classes III, IV, and V LN), anti-dsDNA titers were
reduced and C3 levels increased; however time to renal flare
and number of renal flares—while lower—were not sig-
nificantly different from the placebo group. Subgroup
analysis revealed that patients with high-affinity anti-dsDNA
antibodies had a significantly improved treatment response,
with 8% of the abetimus treatment group flaring in
comparison to 22% of the placebo group.58 However, in
the larger Phase III trial, which specifically enrolled patients
with high-affinity antibodies, the benefit was much less
impressive, with 12% of LJP 394-treated patients flaring,
in comparison with 16% of placebo-treated patients.59
Abetimus is currently being reevaluated in LN patients
in a multinational trial (ClinicalTrials.gov Identifier:
NCT00089804).
Inhibiting costimulatory molecule CD28:B7 interaction with
abatacept and belatacept
Tolerance can also be induced by blockade of targets of co-
stimulatory interactions between T cells and B cells. The
CD28:B7 costimulatory interaction was the first to be
elucidated,60 and is the most important antigen-independent
signal driving T-cell activation. CD28 is a glycoprotein
expressed on T cells; its’ cognate ligands on APCs are B7-
1(CD80) and B7-2(CD86). Stimulation of this pathway
occurs when naı¨ve T cells encounter an APC with the
appropriate major histocompatibility complex Class II bound
antigen, and results in T-lymphocyte proliferation and
differentiation. Cytotoxic T-lymphocyte antigen (CTLA4) is
expressed only on activated T cells and also interacts with B7.
However, this interaction leads to inhibition of T-cell
activation, constituting a negative feedback mechanism.
A fusion protein consisting of cytotoxic T-lymphocyte
antigen (CTLA4) combined with immunoglobulin (CTLA4-
Ig, abatacept) binds B7 with a higher affinity than CD28,
thereby inhibiting the costimulatory pathway. Evidence for
the importance of this pathway in autoimmune disease is
suggested by the finding that (NZBxNZW)F1 lupus prone
mice treated with CTLA4-Ig fusion protein had significantly
suppressed anti-dsDNA titers, decreased incidence of protei-
nuria, and improved survival while maintaining B-lympho-
cyte numbers.61 In other studies using (NZBxNZW)F1 mice,
animals simultaneously treated with CTLA4-Ig and anti-
mouse CD15462 (another T-cell costimulatory ligand) or
cyclophosphamide63 had slower disease progression and
improved survival compared with mice not treated with
CTLA4-Ig. Two formulations of CTLA4-Ig have been used in
humans, abatacept, and belatacept. Abatacept has been used
with success in the treatment of psoriasis and rheumatoid
arthritis,64,65 and belatacept was found to be as efficacious as
cyclosporine in the prevention of acute allograft rejection
in a Phase II clinical trial.66 Based on these experiences, an
open-label pilot trial of CTLA4-IgG4m in combination
with cyclophosphamide in patients with SLE nephritis is
underway.67,68
Inhibiting costimulatory molecule CD40:CD40 ligand (CD
154) interaction with BG9588 and IDEC 131
The interaction between CD40 on B-cells and T-cell CD40L
(or CD154) is another important costimulatory signal for
lymphocyte proliferations and activation.69 CD40 is a 48 kDa
transmembrane glycoprotein found on the surface of
B lymphocytes and is a member of the TNF-receptor family.
CD154 is a 39 kDa transmembrane protein that is a member
of the TNF superfamily found on activated T- and
B lymphocytes. This interaction provides growth signals to
B cells and influences cell-mediated immunity. CD40 signaling
in the presence of appropriate cytokines results in B-cell
proliferation and differentiation into immunoglobulin-
secreting cells. CD154:CD40 interactions are typical of
germinal center reactions, where cells show markers char-
acteristic of activation, proliferation, and secretion.70 Block-
ade of this interaction ameliorates nephritis in lupus-prone
(NZBxNZW)F1 mice.62,71 Evidence for the importance of
this pathway in human SLE is suggested by the finding that
remission of proliferative LN following B-cell depletion
therapy is preceded by downregulation of the T-cell co-
stimulatory molecule CD40L.39 IDEC-131 and BG9588 are
humanized monoclonal antibodies to CD154/CD40L. Of
interest, patients with Class IV proliferative LN, who were
treated with BG9588, showed a shift in peripheral B-cells
markers away from a pattern typical of intensive germinal
center activity, suggesting that germinal center activity is an
important feature of the propensity to produce autoanti-
bodies and disease.70 In a small open-label study to establish
safety and efficacy, 28 patients with active proliferative LN
(mean 3.26 g day1 urinary protein excretion, creatinine
clearance 114 ml per min per 1.73 m2) were treated with
BG9588 at doses of 20 mg kg1 at biweekly intervals for the
first three doses and at monthly intervals for four additional
doses. There was improvement in titers of anti-dsDNA titers
and approximately 50% reduction in proteinuria in response
to treatment; however, the trial was terminated early because
of the incidence of thromboembolic events in patients
receiving the study drug—namely, two nonfatal myocardial
infarctions,72 perhaps as a result of CD154 expression on
activated platelets.73 Although IDEC-131 was found to be
safe in a Phase I clinical trial,74 a Phase II, double-blind,
placebo-controlled, multicenter study enrolling 85 patients
with mild-to-moderate active SLE with a follow-up of 20
weeks demonstrated no improvement in outcomes over
placebo (or increase in thromboembolic incidents).69
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Blockade of B-cell stimulatory cytokine BLyS by belimumab
An alternative approach to targeting B cells is to block
cytokines that are required for B-cell function. A multitude of
cytokines are overexpressed in autoimmune disease, and the
development of cytokine depleting agents has naturally led to
the exploration of their use in SLE.75,76
BLyS, also known as BAFF, is a 285 amino-acid member of
the TNF ligand superfamily.77 It binds to three different
receptors—BCMA, BAFFR, and TACI. It is essential for
B-cell survival and development. Mice genetically deficient in
BlyS/BAFF show reductions in mature B cells and immuno-
globulin levels.78 Overexpression of BlyS/BAFF in trans-
genic mice, conversely, leads to B-cell expansion,
hypergammaglobulinemia, and autoimmunity.79,80 Elevated
BlyS levels have been documented in lupus-prone mice and
in human SLE.81,82 Belimumab (LymphoStat-B) is a fully
humanized monoclonal antibody against BlyS/BAFF, which
can cause depletion of circulating B cells. Preliminary results
from a Phase II clinical trial enrolling 449 SLE patients with
moderate disease activity show improvements in disease
activity and quality of life scores.83 Controlled clinical trials
in SLE nephritis are warranted. TACI-Ig—an alternative
method for blockade of BlyS—is also under development as a
treatment for SLE.84
CONCLUSIONS
B-cell-targeted therapies offer the possibility of treatments for
SLE/LN that are effective and have improved toxicity profiles.
Goals for new therapies of LN are: (1) prevention of relapse,
(2) improved side effect profile, (3) treatment of refractory
disease, and (4) prevention of the development of chronic
interstitial fibrosis and progressive renal failure or end-stage
renal disease. Despite the considerable promise shown by
newer therapies, it is important to note that only three drugs
are approved by the United States Food and Drug Admin-
istration for treatment of SLE—corticosteroids, hydroxy-
chloroquine, and low-dose aspirin—and no new therapies
have been approved in nearly 40 years.85 While clinical trials
of several novel drugs are underway, clinicians and regulatory
bodies must pay close attention to unusual adverse events,
such as progressive multifocal leukoencephalopathy in SLE
patients treated with rituximab, and life threatening compli-
cations with anti-CD28 monoclonal antibodies in healthy
volunteers.86 On the other hand, LN is associated with
considerable morbidity, and efficacious new treatments must
be made available to patients as expeditiously as is reason-
able. Treatment plans need to be individualized for each
patient. Furthermore, the exact role of these agents in the
ever-expanding arsenal of medications needs to be better
defined; that is, are these medications appropriate for
induction and maintenance treatments? Should they be used
as first line therapies or should they be reserved for refractory
disease? Further carefully conducted clinical trials are needed.
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